Alignment Healthcare, Inc. $ALHC Stock Position Raised by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 5.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 13,968,584 shares of the company’s stock after buying an additional 664,769 shares during the quarter. Vanguard Group Inc. owned 0.07% of Alignment Healthcare worth $243,752,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. lifted its stake in Alignment Healthcare by 4,868.9% in the second quarter. SBI Securities Co. Ltd. now owns 3,031 shares of the company’s stock valued at $42,000 after acquiring an additional 2,970 shares during the last quarter. KBC Group NV bought a new position in shares of Alignment Healthcare during the 2nd quarter valued at $44,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Alignment Healthcare in the 3rd quarter valued at $53,000. PNC Financial Services Group Inc. boosted its holdings in Alignment Healthcare by 205.6% in the third quarter. PNC Financial Services Group Inc. now owns 3,459 shares of the company’s stock worth $60,000 after purchasing an additional 2,327 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in Alignment Healthcare by 32.9% during the second quarter. Ameritas Investment Partners Inc. now owns 13,031 shares of the company’s stock worth $182,000 after buying an additional 3,225 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ALHC shares. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. TD Cowen upped their target price on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. The Goldman Sachs Group reiterated a “buy” rating and set a $22.00 price target on shares of Alignment Healthcare in a report on Monday, November 3rd. Finally, UBS Group lifted their price target on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, January 14th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.95.

Alignment Healthcare Price Performance

NASDAQ ALHC opened at $19.22 on Friday. The stock has a 50-day simple moving average of $20.99 and a 200 day simple moving average of $18.54. Alignment Healthcare, Inc. has a twelve month low of $11.63 and a twelve month high of $23.87. The stock has a market capitalization of $3.85 billion, a PE ratio of -1,920.08, a P/E/G ratio of 4.90 and a beta of 1.16. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.61 and a current ratio of 1.61.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.53% and a negative net margin of 0.02%.The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the business posted ($0.16) EPS. The company’s revenue for the quarter was up 44.4% on a year-over-year basis. Research analysts anticipate that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Insider Activity at Alignment Healthcare

In related news, insider Robert L. Scavo sold 69,541 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $18.74, for a total value of $1,303,198.34. Following the completion of the sale, the insider owned 503,014 shares in the company, valued at approximately $9,426,482.36. This trade represents a 12.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John E. Kao sold 605,648 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $18.74, for a total value of $11,349,843.52. Following the transaction, the chief executive officer owned 2,234,294 shares in the company, valued at $41,870,669.56. This represents a 21.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,125,938 shares of company stock worth $41,799,570 in the last ninety days. 7.00% of the stock is currently owned by insiders.

Key Headlines Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q4 results beat near‑term expectations — Alignment reported ($0.05) EPS vs. consensus (~$0.15 loss) and revenue of ~$1.01B, up ~44% year‑over‑year, showing strong top‑line growth. Alignment Healthcare Reports Fourth Quarter and Full‑Year 2025 Results
• Positive Sentiment: Company highlighted record revenue and membership gains, supporting continued Medicare Advantage enrollment momentum that underpins revenue visibility. Alignment Healthcare Inc (ALHC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst writeups and metric comparisons confirmed the beat but note persistent negative margins and ROE; these pieces provide context on profitability trends and model updates. Zacks — Key Metrics Versus Estimates
• Neutral Sentiment: Conference call / press release and filings are available for details on membership trends, medical cost assumptions and guidance drivers for 2026. Quarterly Report / Press Release PDF
• Neutral Sentiment: Reported short‑interest data in public feeds appears erroneous (zeros/NaN); no reliable short‑interest signal from those entries. Market data / profile
• Negative Sentiment: Forward guidance disappointed: Q1 revenue guidance (~$1.2B) below the ~ $1.3B street estimate and FY 2026 revenue guidance of $5.1B–$5.2B sits at or slightly under consensus — investors reacted to the softer top‑line outlook. Guidance details in Earnings Release
• Negative Sentiment: Profitability remains a concern — the company still shows a small negative net margin and negative return on equity, and management did not provide explicit EPS guidance for 2026, leaving investors uncertain on near‑term earnings conversion. Zacks — Q4 Loss, Beats Revenue Estimates

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.